BCIQ Profiles

Company Profile ReportTarget Profile Report

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

Evive planning BLA, MAA for neutropenia therapy following pivotal trial readout
Evive Biotech Inc. said efbemalenograstim alfa met the primary and secondary endpoints in a Phase III study to prevent chemotherapy-induced neutropenia in breast cancer patients. The long-acting dimeric fusion protein containing G-CSF and

Read the full 436 word article

How to gain access

Continue reading with a
two-week free trial.